ArticleActa biochimica Polonica2026
Diagnostic value of endothelial-specific molecule-1 levels in patients with bone tumors.
Article in Acta biochimica Polonica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In suspected bone tumors where imaging and histopathological evaluation are fundamental for diagnosis, minimally invasive blood biomarkers are needed for earlier diagnosis, initial assessment, and risk stratification. The aim of this research was to evaluate the diagnostic value of Endothelial-Specific Molecule-1 (ESM-1) levels in determining the presence of bone tumors and distinguishing between benign and malignant tumors. Methods: This cross-sectional research, conducted at a research hospital, involved 60 participants diagnosed with bone tumors and 30 healthy participants. ESM-1 values were analyzed using Enzyme-Linked Immunosorbent Assay (ELISA). The data obtained were evaluated using binary logistic regression analysis and Receiver Operating Characteristic (ROC) curve analysis. Results: ESM-1 values were determined to be higher in the bone tumors group than in the control group. ROC analysis showed an Area Under the Curve (AUC) of 0.895. Using a cut-off value of 138.94 ng/L for detecting bone tumors, the sensitivity and specificity were 78.3% and 80.0%, respectively. In addition, ESM-1, erythrocyte sedimentation rate, and C-reactive protein levels were found to be higher in the malignant subgroup than in the benign subgroup. In subgroup ROC analysis, ESM-1 perfectly discriminated against malignant tumors from both benign tumors (AUC = 1.000) and healthy controls (AUC = 1.000), with sensitivities and specificities of 100% at cut-off values of 204.54 ng/L and 195.00 ng/L, respectively. For differentiating benign tumors from healthy controls, the AUC was 0.789, with 70.0% sensitivity and 70.0% specificity at a cut-off value of 125.54 ng/L. Conclusion: ESM-1 levels may have potential diagnostic value in distinguishing between bone tumors and malignant tumors; however, these results need to be confirmed in larger samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.